Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies.

Freimoser-Grundschober A, Rueger P, Fingas F, Sondermann P, Herter S, Schlothauer T, Umana P, Neumann C.

J Chromatogr A. 2019 Sep 18:460554. doi: 10.1016/j.chroma.2019.460554. [Epub ahead of print]

PMID:
31597603
2.

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab.

Agez M, Mandon ED, Iwema T, Gianotti R, Limani F, Herter S, Mössner E, Kusznir EA, Huber S, Lauer M, Ringler P, Ferrara C, Klein C, Jawhari A.

Sci Rep. 2019 Sep 23;9(1):13675. doi: 10.1038/s41598-019-50031-4.

3.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.

PMID:
31189721
4.

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.

Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F.

Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8.

5.

p95HER2-T cell bispecific antibody for breast cancer treatment.

Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaat1445. doi: 10.1126/scitranslmed.aat1445.

6.

Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.

Hassenrück F, Knödgen E, Göckeritz E, Midda SH, Vondey V, Neumann L, Herter S, Klein C, Hallek M, Krause G.

Biomed Res Int. 2018 Mar 19;2018:1023490. doi: 10.1155/2018/1023490. eCollection 2018.

7.

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P.

Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1.

8.

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.

Palazzo A, Herter S, Grosmaire L, Jones R, Frey CR, Limani F, Bacac M, Umana P, Oldham RJ, Marshall MJE, Cox KL, Turaj AH, Cragg MS, Klein C, Carter MJ, Tannheimer S.

J Immunol. 2018 Apr 1;200(7):2304-2312. doi: 10.4049/jimmunol.1700323. Epub 2018 Feb 16.

9.

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Herter S, Herting F, Muth G, van Puijenbroek E, Schlothauer T, Ferrara C, Brady K, Lang S, Bacac M, Mössner E, Umana P, Klein C.

Haematologica. 2018 Feb;103(2):e78-e81. doi: 10.3324/haematol.2017.178996. Epub 2017 Oct 27. No abstract available.

10.

Mapping the substrate scope of monoamine oxidase (MAO-N) as a synthetic tool for the enantioselective synthesis of chiral amines.

Herter S, Medina F, Wagschal S, Benhaïm C, Leipold F, Turner NJ.

Bioorg Med Chem. 2018 Apr 1;26(7):1338-1346. doi: 10.1016/j.bmc.2017.07.023. Epub 2017 Jul 13.

PMID:
28764963
11.

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.

Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M.

Cancer Immunol Immunother. 2017 Jan;66(1):129-140. doi: 10.1007/s00262-016-1927-1. Epub 2016 Nov 17.

12.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E.

Protein Eng Des Sel. 2016 Oct;29(10):457-466. doi: 10.1093/protein/gzw040. Epub 2016 Aug 29.

PMID:
27578889
13.

Whole-cell microtiter plate screening assay for terminal hydroxylation of fatty acids by P450s.

Weissenborn MJ, Notonier S, Lang SL, Otte KB, Herter S, Turner NJ, Flitsch SL, Hauer B.

Chem Commun (Camb). 2016 May 4;52(36):6158-61. doi: 10.1039/c6cc01749e. Epub 2016 Apr 14.

PMID:
27074906
14.

Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).

Herting F, Herter S, Friess T, Muth G, Bacac M, Sulcova J, Umana P, Dangl M, Klein C.

Eur J Haematol. 2016 Nov;97(5):461-470. doi: 10.1111/ejh.12756. Epub 2016 Apr 18.

PMID:
26993060
15.

Enantioselective Benzylic Hydroxylation Catalysed by P450 Monooxygenases: Characterisation of a P450cam Mutant Library and Molecular Modelling.

Eichler A, Gricman Ł, Herter S, Kelly PP, Turner NJ, Pleiss J, Flitsch SL.

Chembiochem. 2016 Mar 2;17(5):426-32. doi: 10.1002/cbic.201500536. Epub 2016 Feb 16.

PMID:
26698167
16.

Active site diversification of P450cam with indole generates catalysts for benzylic oxidation reactions.

Kelly PP, Eichler A, Herter S, Kranz DC, Turner NJ, Flitsch SL.

Beilstein J Org Chem. 2015 Sep 22;11:1713-1720. doi: 10.3762/bjoc.11.186. eCollection 2015.

17.

Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy.

Gonzalez-Nicolini V, Herter S, Lang S, Waldhauer I, Bacac M, Roemmele M, Bommer E, Freytag O, van Puijenbroek E, Umaña P, Gerdes CA.

Clin Cancer Res. 2016 May 15;22(10):2453-61. doi: 10.1158/1078-0432.CCR-14-2579. Epub 2015 Nov 18.

18.

Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.

Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M.

J Immunol. 2014 Mar 1;192(5):2252-60. doi: 10.4049/jimmunol.1301249. Epub 2014 Jan 31.

19.

[Therapeutic climbing with psychiatric patients. "On the wall, I finally dared to speak"].

Berclaz J, Cordonier I, Herter S.

Krankenpfl Soins Infirm. 2013;106(7):68-70. French. No abstract available.

PMID:
23894880
20.

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.

21.

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.

22.

Investigating the effects of metals on phenol oxidase-producing nitrogen-fixing Azotobacter chroococcum.

Herter S, Schmidt M, Thompson ML, Mikolasch A, Schauer F.

J Basic Microbiol. 2013 Jun;53(6):509-17. doi: 10.1002/jobm.201100443. Epub 2012 Sep 7.

PMID:
22961388
23.

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C.

Arch Biochem Biophys. 2012 Oct 15;526(2):206-18. doi: 10.1016/j.abb.2012.03.016. Epub 2012 Mar 21.

PMID:
22464987
24.

Study of enzymatic properties of phenol oxidase from nitrogen-fixing Azotobacter chroococcum.

Herter S, Schmidt M, Thompson ML, Mikolasch A, Schauer F.

AMB Express. 2011 Jun 24;1(1):14. doi: 10.1186/2191-0855-1-14.

25.

Identification of phenylalkane derivatives when Mycobacterium neoaurum and Rhodococcus erythropolis were cultured in the presence of various phenylalkanes.

Herter S, Mikolasch A, Schauer F.

Appl Microbiol Biotechnol. 2012 Jan;93(1):343-55. doi: 10.1007/s00253-011-3415-z. Epub 2011 Jun 24.

PMID:
21701983
26.

A new phenol oxidase produced during melanogenesis and encystment stage in the nitrogen-fixing soil bacterium Azotobacter chroococcum.

Herter S, Schmidt M, Thompson ML, Mikolasch A, Schauer F.

Appl Microbiol Biotechnol. 2011 May;90(3):1037-49. doi: 10.1007/s00253-011-3093-x. Epub 2011 Feb 16.

PMID:
21327414
27.

Comparative analysis of tertiary alcohol esterase activity in bacterial strains isolated from enrichment cultures and from screening strain libraries.

Herter S, Nguyen GS, Thompson ML, Steffen-Munsberg F, Schauer F, Bornscheuer UT, Kourist R.

Appl Microbiol Biotechnol. 2011 May;90(3):929-39. doi: 10.1007/s00253-011-3124-7. Epub 2011 Feb 12.

PMID:
21318363
28.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P.

Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1.

29.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.

31.

Correlation of dendritic cell maturation and the formation of aggregates of poly-ubiquitinated proteins in the cytosol.

Fassbender M, Herter S, Holtappels R, Schild H.

Med Microbiol Immunol. 2008 Jun;197(2):185-9. doi: 10.1007/s00430-008-0091-4. Epub 2008 Mar 14. Review.

PMID:
18340462
32.

Cytomegalovirus encodes a positive regulator of antigen presentation.

Holtappels R, Gillert-Marien D, Thomas D, Podlech J, Deegen P, Herter S, Oehrlein-Karpi SA, Strand D, Wagner M, Reddehase MJ.

J Virol. 2006 Aug;80(15):7613-24.

33.

Dendritic cell aggresome-like-induced structure formation and delayed antigen presentation coincide in influenza virus-infected dendritic cells.

Herter S, Osterloh P, Hilf N, Rechtsteiner G, Höhfeld J, Rammensee HG, Schild H.

J Immunol. 2005 Jul 15;175(2):891-8.

34.

Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ.

Biochem J. 2005 Aug 15;390(Pt 1):125-36.

36.

A bicyclic autotrophic CO2 fixation pathway in Chloroflexus aurantiacus.

Herter S, Fuchs G, Bacher A, Eisenreich W.

J Biol Chem. 2002 Jun 7;277(23):20277-83. Epub 2002 Apr 2.

37.

The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway.

Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, Kirschning CJ, Da Costa C, Rammensee HG, Wagner H, Schild H.

J Biol Chem. 2002 Jun 7;277(23):20847-53. Epub 2002 Mar 23.

38.

Autotrophic CO(2) fixation by Chloroflexus aurantiacus: study of glyoxylate formation and assimilation via the 3-hydroxypropionate cycle.

Herter S, Farfsing J, Gad'On N, Rieder C, Eisenreich W, Bacher A, Fuchs G.

J Bacteriol. 2001 Jul;183(14):4305-16.

39.

Complex I of Rhodobacter capsulatus and its role in reverted electron transport.

Herter SM, Kortlüke CM, Drews G.

Arch Microbiol. 1998 Feb;169(2):98-105.

PMID:
9446680
40.
41.

Phenotypic characterization of androgen receptor-related proliferation in prostatic-carcinoma derived cell-cultures.

Zwergel T, Burk U, Herter S, Lindenmeir T, Wullich B, Unteregger G.

Int J Oncol. 1995 Dec;7(6):1339-47.

PMID:
21552970

Supplemental Content

Loading ...
Support Center